Physical Therapists in Watkins Glen, NY Accepting Medicare
6 Physical Therapists found. Showing 1 - 6
 Dr. Sara Diehr, PT, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 609 N Franklin St, Watkins Glen, NY 14891 Phone: 607-535-7475 |
 Seneca Physical Therapy Of The Finger Lakes, Pc Physical Therapist Medicare: Medicare Enrolled Practice Location: 609 N Franklin St, Watkins Glen, NY 14891 Phone: 607-535-7475 |
Lindsey E Perigo, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 609 N Franklin St, Watkins Glen, NY 14891 Phone: 607-535-7574 Fax: 607-535-7445 |
Ashley Alteri-cowen, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 609 N Franklin St, Watkins Glen, NY 14891 Phone: 607-535-7475 Fax: 607-535-7445 |
Honora Clare De Mott Grady, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 609 N Franklin St, Watkins Glen, NY 14891 Phone: 607-535-7475 |
Amanda Smith-socaris, P.T. Physical Therapist - Orthopedic Medicare: Accepting Medicare Assignments Practice Location: 609 N Franklin St, Watkins Glen, NY 14891 Phone: 607-535-7475 Fax: 607-535-7445 |
News Archive
ImmunoCellular receives FDA IND clearance for ICT-121 Phase I trial in glioblastoma multiforme
ImmunoCellular Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUC's novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors.
NIAID exercises option to advance development of Soligenix's heat stabilized ricin toxin vaccine
Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the National Institute of Allergy and Infectious Diseases has exercised its option to advance the development of Soligenix's heat stabilized ricin toxin vaccine, RiVax.
ISTA Pharmaceuticals' presentations on Phase 3 clinical results of Bepreve
ISTA Pharmaceuticals, Inc. today announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis. The studies demonstrated Bepreve was safe and well-tolerated when given twice daily for six weeks in a healthy pediatric population as young as three years of age.
Finance Democrats approve overhaul measure with boost from Snowe
The Senate Finance Committee approved its long-anticipated version of the health-care overhaul legislation in a 14-9 vote Tuesday, the Wall Street Journal reports. Sen. Olympia Snowe, R-Maine, joined the panels 13 Democrats to support the bill.
Study identifies prognostic value of IDH and CIC mutations for grade II/III glioma patients
NRG Oncology investigators have identified two biomarkers that are prognostic of overall and progression-free survival for patients with lower-grade gliomas.
› Verified 7 days ago
Physical Therapists
Chiropractors
Optometrists
Occupational Therapists